Abstracts tagged "Drug toxicity"

Abstract Number: 0337 • ACR Convergence 2024
Characterization of Statin Induced Myopathy in the Hospital Setting
Olivia Yang¹, KUMAR VENKAT², Jeffery Durbin³ and Scott Kubomoto¹, ¹Riverside Community Hospital, Riverside, CA, ²Voluntary Clinical Associate Professor of Medicine -UCRSOM, Riverside, California, IRVINE, CA, ³HCA Healthcare Physicians Services Group, Brentwood, TN
Background/Purpose: Adverse effects of statin use involve the muscle and related rhabdomyolysis. Known risk factors for rhabdomyolysis include female sex, older age, Asian race, hypothyroidism,…
Abstract Number: 1243 • ACR Convergence 2024
A Patient-Focused Program for Using Steroids Wisely
John Stone¹, Michelle Petri², Jeffrey Gelfand³, Camille Kotton⁴, Jane McDowell⁵, George Papaliodis⁶, meredith Marinaro⁷, Matt Wilkinson⁸, Walter Lentfert⁹ and Martha Stone¹⁰, ¹Massachusetts General Hospital , Harvard Medical School, Concord, MA, ²Johns Hopkins University School of Medicine, Timonium, MD, ³University of California, San Francisco, San Francisco, CA, ⁴Harvard Medical School, Boston, MA, ⁵Queens University Belfast, Belfast, Ireland, ⁶Massachusetts General Hospital, Boston, MA, ⁷Novartis, Hartford, CT, ⁸UpThereEverywhere, London, United Kingdom, ⁹UpThereEverywhere, Wilmington, NC, ¹⁰Steritas, LLC, CONCORD, MA
Background/Purpose: Patients have no comprehensive, curated resource on steroid use to facilitate effective collaboration in their own care. Consequently, truly shared decision making around steroid…
Abstract Number: 0363 • ACR Convergence 2024
Comparative Risk of Demyelinating Diseases Among Patients on TNF-Alpha Inhibitors: A Cohort Study Using the TriNetX Database
Rafal Ali¹, Yurilu Gonzalez Moret², Roua Hussein³ and Fabian Rodriguez⁴, ¹Jefferson Einstein Philadelphia, Lansdale, PA, ²Jefferson Einstein Philadelphia, Philadelphia, PA, ³Al-Mustansiriyah University/ college of medicine, New York, NY, ⁴Jefferson Einstein Hospital, Philadelphia, PA
Background/Purpose: TNF-alpha inhibitors are widely used in the field of rheumatology and have been linked to various possible adverse events, including demyelinating diseases. This association…
Abstract Number: 1949 • ACR Convergence 2024
Implementation of Pharmacist-Led Comprehensive Medication Management for Puerto Ricans with Rheumatic Diseases
Ileana Rodriguez Nazario, Kyle Melin and Luis Vilá, University of Puerto Rico Medical Sciences Campus, San Juan, PR
Background/Purpose: Comprehensive Medication Management (CMM) is a standardized intervention provided by clinical pharmacists that uses subjective and objective patient information to create a plan to…
Abstract Number: 0376 • ACR Convergence 2024
Preliminary Results of the Ondansetron Pre-medication Trial in Juvenile Idiopathic Arthritis: A Pragmatic Randomized Controlled Trial Nested in the CAPRI Registry
Gaelle Chedeville¹, Heinrike Schmeling², Jean-Philippe Proulx-Gauthier³, Michelle Batthish⁴, Jean Jacques De Bruycker⁵, Brian Feldman⁶, Roberta A Berard⁷, Roxana Bolaria⁸, Amieleena Chhabra⁹, Lily Lim¹⁰, Adam Huber¹¹, Matthew Berkowitz¹², Thomas Loughin¹² and Jaime Guzman¹³, and CAPRI Registry Investigators, ¹The Montreal Children's Hospital, Montreal, QC, Canada, ²University of Calgary, Calgary, AB, Canada, ³CHU de Quebec - Universite Laval, Quebec, QC, Canada, ⁴McMaster Children's Hospital, Hamilton, ON, Canada, ⁵UNIVERSITY OF MONTREAL, Montreal, QC, Montreal, QC, Canada, ⁶Division of Rheumatology, The Hospital for Sick Children; Departments of Pediatrics and Medicine, Faculty of Medicine; The Institute for Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ⁷London Health Sciences Centre, London, ON, Canada, ⁸Victoria Arthritis Center, Victoria, BC, Canada, ⁹University of British Columbia, Penticton, BC, Canada, ¹⁰University of Manitoba, Winnipeg, MB, Canada, ¹¹IWK Health Centre, Halifax, NS, Canada, ¹²Simon Fraser University, Burnaby, BC, Canada, ¹³University of British Columbia and BC Children's Hospital, Vancouver, BC, Canada
Background/Purpose: About 50% of children with Juvenile Idiopathic Arthritis (JIA) receiving methotrexate (MTX) develop MTX intolerance with severe anticipatory nausea/vomiting and avoidance behaviors. Intolerance often…
Abstract Number: 1986 • ACR Convergence 2024
Disease Flare Following Immune Checkpoint Inhibition in Patients with Cancer and Preexisting Vasculitis
Juan Sevillano¹, Yixuan Zhou², Juan Ruiz³, Noha Abdel-Wahab⁴ and Maria Suarez-Almazor¹, ¹MD Anderson Cancer Center, Houston, TX, ²Baylor College of Medicine, Houston, ³MD Anderson, Houston, TX, ⁴University of Texas MD Anderson Cancer Center, houston, TX
Background/Purpose: Immune checkpoint inhibitors (ICI) are effective therapies for patients with cancer, but they often cause immune-related adverse events (irAE). There is limited data on…
Abstract Number: 0439 • ACR Convergence 2024
Contraception Counseling and Contraception Use Among SLE and RA/JIA Patients at a Public Medical Center in Los Angeles: Investigating Teratogenic Medication Use and Language Preferences
Laura Kobashigawa¹, Cassidy Hernandez-Tamayo², Katherine Ruddy³, Melissa Wilson² and Leanna Wise⁴, ¹University of Southern California/Los Angeles General Medical Center, Pasadena, CA, ²Keck School of Medicine of USC, Los Angeles, CA, ³University of Southern California/ Los Angeles General Medical Center, Los Angeles, CA, ⁴LAC+USC/Keck Medicine of USC, Pasadena, CA
Background/Purpose: Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)/juvenile idiopathic arthritis (JIA) frequently impact women of reproductive age. Management of these patients is particularly important…
Abstract Number: 1997 • ACR Convergence 2024
Features of interleukin-1 and interleukin-6 Inhibitor (IL-1i/IL-6i) Related Severe Delayed Adverse Reactions in Subjects with or Without Reaction-risk Associated HLA-DRB1*15
Vivian E Saper¹, Kazutoyo Osoegawa¹, Ruud Verstegen², Marcelo A Fernandez Vina¹ and Lu Tian¹, and Drug Hypersensitivity Consortium, ¹Stanford University, Stanford, CA, ²The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: A very serious drug-related adverse event is reported with inhibitors of IL-1 and IL-6 (IL-1i/IL6i). This reaction scores as drug reaction with eosinophilia and…
Abstract Number: 0441 • ACR Convergence 2024
A Qualitative Improvement Project to Incorporate the Mycophenolate Risk Evaluation and Mitigation Strategies in an Academic Lupus Clinic
Dahima Cintron¹, Jennifer Rogers², Rebecca Sadun¹, Mithu Maheswaranathan³, Kai Sun¹, Jayanth Doss¹, Lisa Criscione-Schreiber³ and Megan Clowse⁴, ¹Duke University, Durham, NC, ²Duke, Durham, NC, ³Duke University School of Medicine, Durham, NC, ⁴Duke University, Chapel Hill, NC
Background/Purpose: Mycophenolate Mofetil/Mycophenolic acid (MMF) is an immunosuppressant used to treat SLE. Due to the teratogenic effects of MMF, the FDA recommended universal risk evaluation…
Abstract Number: 2000 • ACR Convergence 2024
Induction of Systemic Inflammatory Diseases with Dupilumab Therapy
Jeanne Tisseau des Escotais¹, Camille Taille², Julie Merindol³, Matthieu Groh⁴, Perrine SMETS⁵, Amel Boudjemaa⁶, Alexandra Audemard⁷, Nabil Belfeki⁸, Philippe Bonniaud⁹, Chloe Comarmond¹⁰, Isabelle DELACROIX¹¹, Charlotte Descours¹², Lucile Grange¹³, Paul Legendre¹⁴, Nihal Martis¹⁵, Thomas Moulinet¹⁶, Béatrice Walls¹⁷, Laurent Chouchana¹ and Benjamin Terrier¹⁸, ¹Cochin, Paris, France, ²Bichat Hospital, Paris, France, ³Internal Medicine Department, University Hospital of Nice, Côte d'Azur University, Nice, Provence-Alpes-Côte d'Azur, France., Nice, France, ⁴Foch, Suresnes, France, ⁵Clermont Ferrand University Hospital - National reference center for autoimmune disease, Internal Medicine, Clermont-Ferrand, France, ⁶CHU créteil, Créteil, France, ⁷Tours, Tours, France, ⁸CH Melun, Melun, France, ⁹Centre de Référence Constitutif des Maladies Pulmonaires Rares de l'Adulte, Service de Pneumologie et Soins Intensifs Respiratoires, Centre Hospitalo-Universitaire de Dijon-Bourgogne, Dijon, France, ¹⁰Lariboisière University Hospital, Paris, France, ¹¹CHI créteil, Créteil, France, ¹²CH Tours, Tours, France, ¹³CH Saint-Etienne, Saint-Etienne, France, ¹⁴Service Médecine Interne et Polyvalente, Centre Hospitaliers Le Mans, Le Mans, France, ¹⁵CH Nice, Nice, France, ¹⁶CHRU de Nancy, Vandœuvre-lès-Nancy, France, ¹⁷Paris, Paris, France, ¹⁸Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France
Background/Purpose: Dupilumab is a monoclonal antibody directed against the alpha subunit of the interleukin (IL)-4 receptor, blocking interleukin (IL)-4 and IL-13 signaling. It is approved…
Abstract Number: 0537 • ACR Convergence 2024
Evaluating the Usage of Janus Kinase Inhibitors in Rheumatology and Its Impact on Cardiovascular Risk
Knkush Hakobyan¹, Talar Acob², Mesrop Aleksanyan³, Tigran Kakhktsyan³, Omar Jumaah³ and Sajina Prabhakaran⁴, ¹Capital Health medical center, Princeton, NJ, ²College of medicine-university of Baghdad, Plainsboro Township, NJ, ³Capital Health Medical Center, Trenton, ⁴Capital health Rheumatology specialists, Newtown, PA
Background/Purpose: Janus kinase (JAK) inhibitors have been widely used in treatingrheumatological conditions like rheumatoid arthritis and psoriatic arthritis. Despite theirefficacy, there are concerns regarding major…
Abstract Number: 2004 • ACR Convergence 2024
Rheumatic Complications Post-CAR-T Cell Therapy. Experience of a Single Center
Jose Alfredo Gomez-Puerta¹, Ana Monegal¹, Andrés Ponce², Pilar Peris³, Nuria Martínez⁴, Valentin Ortiz-Maldonado⁴, Ana Triguero⁴, Carlos Fernández de larrea⁴, Julio Delgado⁴, Raimon Sanmartí Sala¹ and Manuel Juan⁵, ¹Rheumatology Department, Hospital Clinic of Barcelona, Barcelona, Spain, ²Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ³Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ⁴Haematology Department, Hospital Clinic of Barcelona, Barcelona, Spain, ⁵Immunology Department, Hospital Clinic of Barcelona, Barcelona, Spain
Background/Purpose: CAR-T cell therapy is a promising treatment for a range of systemic autoimmune diseases such as systemic lupus erythematosus, systemic sclerosis, and antisynthetase syndrome,…
Abstract Number: 0606 • ACR Convergence 2024
Choice of Biologic Immunotherapy for Psoriasis or Psoriatic Arthritis Not Associated with Risk of Major Adverse Cardiac Events
Bonit Gill¹, Jack Geiger¹, Jean Liew², Michael Putman³ and Shikha Singla¹, ¹Medical College of Wisconsin, Milwaukee, WI, ²Boston University, Boston, MA, ³The Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Individuals with psoriasis or psoriatic arthritis (PsO/PsA) have an elevated risk ofmajor adverse cardiac events (MACE), which include congestive heart failure (CHF), myocardialinfarction (MI),…
Abstract Number: 2121 • ACR Convergence 2024
Increased Fracture Rates in Patients Continuing Methotrexate After Methotrexate-associated Lower Limb Insufficiency Fractures: A Retrospective Follow-up Study
Roba Ghossan¹, OLIVIER FOGEL², Christian Roux¹ and Karine Briot¹, ¹COCHIN HOSPITAL, PARIS, France, ²AP-HP, Paris, France
Background/Purpose: Spontaneous lower limb insufficiency fractures (LLIF) described under prolonged exposure to low-dose methotrexate are often bilateral, multiple, and recurrent. They share a common pathognomonic…
Abstract Number: 0675 • ACR Convergence 2024
Hydroxychloroquine Induced Cardiomyopathy: A Biopsy Proven Case Series
Swetapadma Tripathy¹, Davina Chen², Lanny DiFranza³ and Bibi Ayesha⁴, ¹Montefiore Medical Center, Forest Hills, NY, ²Montefiore Medical Center, New Rochelle, NY, ³Montefiore Medical Center, New York City, NY, ⁴Montefiore Medical Center, Metuchen, NJ
Background/Purpose: Cardiomyopathy is a rare, life-threatening adverse effect of hydroxychloroquine (HCQ) use. There is a paucity in literature regarding treatment and prognosis in these cases. The aim…

1
2
3
…
10
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].